All In MedTech

FDA Clearance Tracker · P060022-S010

AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 21, 2011 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 21, 2011

Approved

Time to decision

247 days

Received Feb 16, 2011. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P060022-S010
Device name
AKREOS POSTERIOR CHAMBER INTRAOCULAR LENS
Applicant location
Irvine, CA
Received
Feb 16, 2011
Decided
Oct 21, 2011
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P060022

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code HQL

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE REMOVAL OF VERBIAGE PERTAINING TO THE CLINICAL ASSESSMENT OF THE ADDITION OF THE ASPHERIC SURFACE.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.